Beckman Coulter s Denham on Targeting the Molecular Dx Market with New Platforms | GenomeWeb

Over the past two months, Beckman Coulter has released its Vidiera NsD nucleic sample detection platform and Vidiera NsP nucleic sample preparation platform. The new instruments are key to the firm's emerging efforts in the molecular diagnostics field. The NsD platform is based on Beckman's capillary electrophoresis technology and was launched last month in the US, with an international roll-out planned for next year. The launch of the NsP, which is based on Beckman's primary tube-handling technology and Biomek automation, was announced last week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.